Conduit Pharmaceuticals/$CDT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Ticker
$CDT
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
6
ISIN
US20678X3044
Website
CDT Metrics
BasicAdvanced
$2.8M
-
-$175.91
2.00
-
Price and volume
Market cap
$2.8M
Beta
2
52-week high
$6.00
52-week low
$2.21
Average daily volume
519K
Financial strength
Current ratio
1.308
Quick ratio
0.576
Long term debt to equity
2.903
Total debt to equity
106.699
Interest coverage (TTM)
-10.54%
Profitability
Management effectiveness
Return on assets (TTM)
-168.26%
Return on equity (TTM)
9,415.53%
Valuation
Price to book
0.69
Price to tangible book (TTM)
0.69
Price to free cash flow (TTM)
-0.027
Free cash flow yield (TTM)
-3,637.69%
Free cash flow per share (TTM)
-10,619.06%
Growth
Earnings per share change (TTM)
4.16%
CDT News
AllArticlesVideos
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
GlobeNewsWire·1 month ago
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
GlobeNewsWire·1 month ago
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Conduit Pharmaceuticals stock?
Conduit Pharmaceuticals (CDT) has a market cap of $2.8M as of July 05, 2025.
What is the P/E ratio for Conduit Pharmaceuticals stock?
The price to earnings (P/E) ratio for Conduit Pharmaceuticals (CDT) stock is 0 as of July 05, 2025.
Does Conduit Pharmaceuticals stock pay dividends?
No, Conduit Pharmaceuticals (CDT) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Conduit Pharmaceuticals dividend payment date?
Conduit Pharmaceuticals (CDT) stock does not pay dividends to its shareholders.
What is the beta indicator for Conduit Pharmaceuticals?
Conduit Pharmaceuticals (CDT) has a beta rating of 2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.